These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 35260039)

  • 21. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
    Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
    J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
    Eckman MH; Woodle ES; Thakar CV; Alloway RR; Sherman KE
    Am J Kidney Dis; 2020 Jun; 75(6):857-867. PubMed ID: 32081494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.
    Bethea ED; Gaj K; Gustafson JL; Axtell A; Lebeis T; Schoenike M; Turvey K; Coglianese E; Thomas S; Newton-Cheh C; Ibrahim N; Carlson W; Ho JE; Shah R; Nayor M; Gift T; Shao S; Dugal A; Markmann J; Elias N; Yeh H; Andersson K; Pratt D; Bhan I; Safa K; Fishman J; Kotton C; Myoung P; Villavicencio MA; D'Alessandro D; Chung RT; Lewis GD
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):771-780. PubMed ID: 31353243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study.
    Crismale JF; Khalid M; Bhansali A; De Boccardo G; Khaim R; Florman SS; Shapiro R; Schiano TD
    Clin Transplant; 2020 Jan; 34(1):e13761. PubMed ID: 31808193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients.
    Stewart ZA; Shah SA; Rolls JA; Guarrera JV; Kandaswamy R; Axelrod DA
    Clin Transplant; 2021 Aug; 35(8):e14381. PubMed ID: 34086371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY
    Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors.
    Smith DE; Chen S; Fargnoli A; Lewis T; Galloway AC; Kon ZN; Moazami N
    Semin Thorac Cardiovasc Surg; 2021; 33(2):407-415. PubMed ID: 32621962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of hepatitis C virus-positive donors in kidney transplantation.
    Shetty A; Ariyamuthu VK; Gungor AB; Tanriover B
    Curr Opin Organ Transplant; 2023 Feb; 28(1):22-28. PubMed ID: 36227758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
    La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
    Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of donor hepatitis C virus infection with 3-year kidney transplant outcomes in the era of direct-acting antiviral medications.
    Sutcliffe S; Ji M; Chang SH; Stewart D; Axelrod DA; Lentine KL; Wellen J; Alrata L; Gupta G; Alhamad T
    Am J Transplant; 2023 May; 23(5):629-635. PubMed ID: 37130619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.
    Reyentovich A; Gidea CG; Smith D; Lonze B; Kon Z; Fargnoli A; Pavone J; Rao S; Saraon T; Lewis T; Qian Y; Jacobson I; Moazami N
    Clin Transplant; 2020 Sep; 34(9):e13989. PubMed ID: 32441413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.
    Bethea E; Arvind A; Gustafson J; Andersson K; Pratt D; Bhan I; Thiim M; Corey K; Bloom P; Markmann J; Yeh H; Elias N; Kimura S; Dageforde LA; Cuenca A; Kawai T; Safa K; Williams W; Gilligan H; Sise M; Fishman J; Kotton C; Kim A; Rogers CC; Shao S; Cote M; Irwin L; Myoung P; Chung RT
    Am J Transplant; 2020 Jun; 20(6):1619-1628. PubMed ID: 31887236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post-transplant viremia.
    Khan S; Mazumder R; Wang X; Wang Y; Sims OT; Budev M; Carey W
    Clin Transplant; 2024 May; 38(5):e15325. PubMed ID: 38716770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.
    Sise ME; Strohbehn IA; Chute DF; Gustafson J; Van Deerlin VM; Smith JR; Gentile C; Wojciechowski D; Williams WW; Elias N; Chung RT
    Kidney Int Rep; 2020 Apr; 5(4):459-467. PubMed ID: 32280841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers.
    Lentine KL; Peipert JD; Alhamad T; Caliskan Y; Concepcion BP; Forbes R; Schnitzler M; Chang SH; Cooper M; Bloom RD; Mannon RB; Axelrod DA
    Kidney360; 2020 Nov; 1(11):1291-1299. PubMed ID: 33251523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation.
    Couri T; Katz J; Stoeckle K; Nugooru A; Yeh H; Chung R; Paul S
    Am J Nephrol; 2019; 50(3):168-176. PubMed ID: 31390615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients.
    Sise ME; Chute DF; Gustafson JL; Wojciechowski D; Elias N; Chung RT; Williams WW
    Hemodial Int; 2018 Apr; 22 Suppl 1():S71-S80. PubMed ID: 29694722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.